A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 17 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors

AMR Benchmark homepage

News - 18 Nov 2021

Now online: 2021 AMR Benchmark

Pharma companies press on in fight against superbugs despite COVID-19 pandemic. But action to improve global access to antibiotics still lags. The AMR Benchmark tracks 17 of the world’s largest pharma companies on their efforts against drug resistance.

The AMR Benchmark: tracking pharma’s response to drug resistance

The 2021 Antimicrobial Resistance Benchmark compares how pharmaceutical companies are tackling this crisis. This independent report covers R&D, responsible manufacturing, access and stewardship.

Key finding

Progress on limiting release of antibiotic waste into environment, but gaps remain

Progress on limiting release of antibiotic waste into environment, but gaps remain

More companies set and enforce limits at their own sites, and are now starting to expand these standards to supplier sites.

Key finding

Pharma companies make limited use of ways to improve access to antibiotics

Pharma companies make limited use of ways to improve access to antibiotics

Just one third of products are covered by any access strategy in any of the low and middle-income countries in scope.

News related to the Antimicrobial Resistance Benchmark

18 Nov 2021

Signs of progress by pharma against superbugs, yet little movement to address access

Pharma companies press on in fight against superbugs despite COVID-19 pandemic, finds the 2021 Antimicrobial Resistance Benchmark.

18 Nov 2021

First Discussion of 2021 AMR Benchmark Findings: A One Health Spotlight on Access, Innovation and Stewardship

On Thursday 18 November, the Foundation will publish its 2021 Antimicrobial Resistance Benchmark, presenting its findings for the first time at a virtual event

16 Jun 2021

Global oxygen suppliers commit to closing oxygen gaps in low- and middle-income countries

Two of the world’s largest medical oxygen suppliers have agreed to work with the COVID-19 Oxygen Emergency Taskforce to increase access to medical oxygen in LMICs.

10 Jun 2021

Biotech’s antibiotic warriors need new reward system in superbug fight

Small drugmakers drive the late-stage antibiotic pipeline. Yet they face bankruptcy, leaving new medicines stranded. This new research shows some are finding novel ways to bring new antibiotics to market.

View all news

"This independent Antimicrobial Resistance Benchmark is a huge step forward and shines a light on the pharmaceutical industry’s progress in tackling drug-resistant infections. It can help pave the way for a transparent learning culture where best practice is shared, progress celebrated, and gaps where further work is needed are identified.”

Dame Sally Davies

Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance and Master of Trinity College, Cambridge

The Antimicrobial Resistance Benchmark is featured in

View our media coverage

Back to top |